The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$5.7M | 3 yrs ago

About Athera Biotechnologies

Athera Biotechnologies develops a biomarker and companion diagnostic VCDefine kit. The biomaker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera's therapeutics.

Athera Biotechnologies Headquarter Location

Sankt Eriksgatan 117 4th floor

Stockholm, SE-113 43,


+46 76 1938 190

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Athera Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Athera Biotechnologies is included in 4 Expert Collections, including Medical Devices.


Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx


Health IT

7,900 items

Athera Biotechnologies Patents

Athera Biotechnologies has filed 14 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • H1 receptor antagonists
  • Muscarinic antagonists
patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Monoclonal antibodies, Immunology, Clusters of differentiation, Immune system


Application Date


Grant Date



Related Topics

Autoimmune diseases, Monoclonal antibodies, Immunology, Clusters of differentiation, Immune system



Latest Athera Biotechnologies News

Last patient dosed in Athera’s Phase 2 study

Apr 2, 2020

Athera Biotechnologies announces that the last patient has been dosed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure. The study completed recruitment by including 82 patients with STEMI and aims for results to be presented in 2020. The target of the study with ATH3G10 was to include approximately 80 patients with acute myocardial infarction and high risk to develop heart failure. Treatment effect is measured by Magnetic Resonance Imaging (MRI) scans that correlate with development of heart failure. A total of 15 hospitals in Sweden, Denmark and The Netherlands have enabled the full recruitment of the study. The proof-of-concept study randomized acute MI patients to one dose of either ATH3G10 or placebo, immediately after the standard of care catheter intervention at acute cardiology units in hospital. The study was started in 2019 with the first patient recruited in April. The extraordinary challenges of the ongoing Covid-19 outbreak Despite current challenges within the health care systems following the Corona-virus outbreak, study recruitment has now been completed according to plan and 82 patients have entered the trial. The study protocol will proceed into the follow-up period, where patients come back for a second MRI-imaging and for regular safety check-up. The study is designed to show if treatment with ATH3G10 significantly decreases the probability for heart failure following myocardial infarction, compared to placebo. “We are very grateful that we were able to complete recruitment of patients to the study according to our plans,” says James Hall, CEO of Athera. “We owe the teams at the acute cardiology units and at the MRI units great respect for their outstanding dedication and active conduct in the study. This has been one of the quickest trials to recruit in this patient population in recent years. We continue to rely heavily on the involvement of the teams and participating patients throughout the follow-up period, despite the extraordinary challenges of the ongoing Covid-19 outbreak.” Photo: Athera Biotechnologies January 20, 2014 Trialbee has developed a web based platform and methodology which enable the Novo Nordisk to perform fast and effective patient recruitment to specific clinical trials. Trialbee helps reduce the time required for recruitment resulting in important efficiency gains for the pharmaceutical company. Novo Nordisk will use Trialbee’s services for e-recruitment… January 12, 2018 The company has received authorization to conduct a phase I/II clinical study on the quadrivalent influenza vaccine candidate Immunose FLU, a novel nose drop formulation based on the company´s technology Endocine and inactivated split antigens. Eurocine Vaccines submitted applications to the Swedish Medical Products Agency, MPA, and to the Ethics… August 29, 2019 The company has announced positive Phase II MERECA results, including complete tumor responses in metastatic renal cell carcinoma patients. The study’s objective was to evaluate the therapeutic impact of combining ilixadencel with Sutent (sunitinib). The most important outcome was achieving five complete responses, defined as eradication of the cancerous tumor… May 19, 2016 Benralizumab, AZ’s potential new medicine and anti-eosinophil monoclonal antibody, has been well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials. This demonstrates significant reductions in the annual asthma exacerbation rate compared to placebo. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said:… Editor in Chief

Athera Biotechnologies Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Athera Biotechnologies Rank

  • When was Athera Biotechnologies founded?

    Athera Biotechnologies was founded in 2002.

  • Where is Athera Biotechnologies's headquarters?

    Athera Biotechnologies's headquarters is located at Sankt Eriksgatan 117, Stockholm.

  • What is Athera Biotechnologies's latest funding round?

    Athera Biotechnologies's latest funding round is Series B.

  • How much did Athera Biotechnologies raise?

    Athera Biotechnologies raised a total of $16.52M.

  • Who are the investors of Athera Biotechnologies?

    Investors of Athera Biotechnologies include The Foundation for Baltic and East European Studies, Industrifonden, Sciety, Linc Invest, Antaros Medical and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.